Details

Autor(en) / Beteiligte

• Chew, Emily Y
• Ambrosius, Walter T
• Davis, Matthew D
• Danis, Ronald P
• Gangaputra, Sapna
• Greven, Craig M
• Hubbard, Larry
• Esser, Barbara A
• Lovato, James F
• Perdue, Letitia H
• Goff, Jr, David C
• Cushman, William C
• Ginsberg, Henry N
• Elam, Marshall B
• Genuth, Saul
• Gerstein, Hertzel C
• Schubart, Ulrich
• Fine, Lawrence J

Titel

Effects of Medical Therapies on Retinopathy Progression in Type 2 Diabetes

Ist Teil von

• The New England journal of medicine, 2010-07, Vol.363 (3), p.233-244

Ort / Verlag

Waltham, MA: Massachusetts Medical Society

Erscheinungsjahr

2010

Quelle

MEDLINE

Beschreibungen/Notizen

• Patients with type 2 diabetes mellitus were evaluated for progression of diabetic retinopathy after being randomly assigned to receive several medical therapies. At 4 years, the rate of progression was significantly lower with intensive glycemia therapy than with standard glycemia therapy and significantly lower with simvastatin plus fenofibrate than with simvastatin plus placebo. Patients with type 2 diabetes mellitus were evaluated for progression of diabetic retinopathy after being randomly assigned to receive several medical therapies. At 4 years, the rate of progression was significantly lower with intensive glycemia therapy than with standard glycemia therapy and significantly lower with simvastatin plus fenofibrate than with simvastatin plus placebo. Diabetic retinopathy, an important microvascular complication of diabetes, is a leading cause of blindness in the United States. 1 Randomized, controlled clinical trials in cohorts of patients with type 1 diabetes and those with type 2 diabetes have shown the beneficial effects of intensive glycemic control 2 – 5 and intensive treatment of elevated blood pressure 6 on the progression of diabetic retinopathy. Elevated serum cholesterol and triglyceride levels have been implicated, in observational studies and small trials, as additional risk factors for the development of diabetic retinopathy and visual loss. 7 – 14 The Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study (Current Controlled . . .